[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].
[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].
复制标题
DOI：
--
复制
发表时间：
2011-12
期刊：
影响因子：
--
通讯作者：
F. Jiang;Li-ping Sun;J. Yang
中科院分区：
文献类型：
--
作者：
F. Jiang;Li-ping Sun;J. Yang
目的研究不同剂量血脂康对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后炎症因子和血脂的影响，探讨其安全性。方法选择择期经皮冠状动脉介入治疗的急性冠脉综合征患者80例，随机分为常规剂量组40例和大剂量消脂康组40例。除常规治疗外，所有患者均每日服用消脂康1.2和0。6克，每日两次。他们从PCI手术的那一天起就开始了XZK。两组疗程均在8周以上。分别于术后1周、4周、8周检测超敏C反应蛋白(hs-CRP)和基质金属蛋白酶-9(MMP9)水平。观察血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDLc)、低密度脂蛋白胆固醇(LDL-C)水平及肝肾功能变化。分析血脂与炎症因子的相关性。记录不良反应情况。结果两组患者术后1周、4周、8周血清hs-CRP、MMP9水平较用药前均有下降，以用药后第8周下降最为显著(P<；0.05)。血脂康大剂量组下降更为明显(P<；0.05)。两组患者术后4、8周血清低密度脂蛋白胆固醇水平均明显下降(P<；0.05)。第8周时，血脂康大剂量组下降更为明显(P<；0.05)。血脂康大剂量组第8周血清hs-C反应蛋白、基质金属蛋白酶-9水平与低密度脂蛋白下降程度呈正相关(r=0.828，0.922，P<0.05)。两组不良反应发生率、肝肾功能均无明显差异。结论消脂康可降低血清hs-CRP、MMP-9、LDL-C水平。血脂康大剂量组疗效更为明显。炎症因子降低的程度与血脂的降低程度相关。
OBJECTIVE To study the effects Xuezhikang (XZK) at different doses on inflammatory factors and blood lipids of patients suffering from acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) and to discuss their safety. METHODS Eighty ACS in patients receiving selective PCI treatment were randomly assigned to two groups, 40 cases in the normal dose group and 40 cases in the large dose XZK group. Besides routine therapy, all patients took XZK at the daily dose of 1.2 and 0. 6 g, twice daily. They started XZK from the very day of PCI operation. The therapeutic course for all was more than 8 weeks. The levels of high sensitivity C reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were detected in the two groups 1 week, 4 and 8 weeks after operation. The levels of TC, TG, HDL-C, LDL-C, changes of liver and renal functions were observed. The correlation between blood lipids and inflammatory factors were analyzed. The adverse reaction was recorded. RESULTS Compared with before medication, the serum levels of hs-CRP and MMP-9 decreased in the two groups 1 week, 4 and 8 weeks after operation, with statistical difference shown in the levels at the 8th week (P < 0.05). The decrease was more obvious in the large dose XZK group (P < 0.05). The LDL-C level obviously decreased in the two groups 4 and 8 weeks after operation (P < 0.05). The decrease was more obvious in the large dose XZK group at the 8th week (P < 0.05). The levels of hs-CRP and MMP-9 were positively correlated with the decrease degree of LDL-C in the large dose XZK group at the 8th week (r = 0.828, 0.922, P < 0.05). There was no significant difference in the occurrence of adverse reaction, hepatic or renal functions between the two groups. CONCLUSIONS XZK could lower the serum levels of hs-CRP, MMP-9, and LDL-C. More obvious effects were obtained in the large dose XZK group. The decrease degree of inflammatory factors was correlated with the decrease extent of blood lipids.